Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4036-4047

  Sung, Pi Lin ^a   Jan, Yi Hua ^b   Lin, Shih Chieh ^c   Huang, Chao Cheng ^d   Lin, Hao ^d   Wen, Kuo Chang ^a   Chao, Kuan Chong ^a   Lai, Chiung Ru ^c   Wang, Peng Hui ^a   Chuang, Chi Mu ^a   Wu, Hua Hsi ^a   Twu, Nae Fang ^a   Yen, Ming Shyen ^a   Hsiao, Michael ^b   Huang, Chi Ying F ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Biomarker; Epithelial ovarian cancer; Microenvironment; Periostin; Platinum resistance

Indexed keywords

CISPLATIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RUNX2; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; TUMOR MARKER;

A2780 CELL LINE; ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMA CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL OVARIAN CARCINOMA; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR MICROENVIRONMENT; UPREGULATION; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; APOPTOSIS; CANCER GRADING; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DRUG EFFECTS; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL PROLIFERATION; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84958025713     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6700     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
2. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004; 351:2519-2529.
3. Thigpen JT, Blessing JA, Ball H, Hummel SJ and Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1994; 12:1748-1753.
4. Takeshita S, Kikuno R, Tezuka K and Amann E. Osteoblastspecific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. The Biochemical journal. 1993; 294:271-278.
5. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF and Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 1999; 14:1239-1249.
6. Norris RA, Damon B, Mironov V, Kasyanov V, Ramamurthi A, Moreno-Rodriguez R, Trusk T, Potts JD, Goodwin RL, Davis J, Hoffman S, Wen X, Sugi Y et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. Journal of cellular biochemistry. 2007; 101:695-711.
7. Morra L, Rechsteiner M, Casagrande S, Duc Luu V, Santimaria R, Diener PA, Sulser T, Kristiansen G, Schraml P, Moch H and Soltermann A. Relevance of periostin splice variants in renal cell carcinoma. The American journal of pathology. 2011; 179:1513-1521.
8. Morra L and Moch H. Periostin expression and epithelialmesenchymal transition in cancer: a review and an update. Virchows Archiv: an international journal of pathology. 2011; 459:465-475.
9. Kii I and Kudo A. [Periostin function in the periodontal ligament and the periosteum]. Clinical calcium. 2007; 17:202-208.
10. Kudo Y, Siriwardena BS, Hatano H, Ogawa I and Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histology and histopathology. 2007; 22:1167-1174.
11. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY and Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002; 62:5358-5364.
12. Hong LZ, Wei XW, Chen JF and Shi Y. Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncology letters. 2013; 6:1595-1603.
13. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC and Chang DD. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer research. 2000; 60:6744-6749.
14. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY and Slamon DJ. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol. 2010; 119:337-344.
15. Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC and Slamon DJ. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Molecular cancer therapeutics. 2011; 10:1500-1508.
16. Morra L, Rechsteiner M, Casagrande S, von Teichman A, Schraml P, Moch H and Soltermann A. Characterization of periostin isoform pattern in non-small cell lung cancer. Lung cancer. 2012; 76:183-190.
17. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T and Lemoine NR. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007; 26:2082-2094.
18. Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, Unno M and Shimosegawa T. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. International journal of cancer Journal international du cancer. 2008; 122:2707-2718.
19. Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK and Shirasawa S. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. The Prostate. 2009; 69:1398-1403.
20. Choi KU, Yun JS, Lee IH, Heo SC, Shin SH, Jeon ES, Choi YJ, Suh DS, Yoon MS and Kim JH. Lysophosphatidic acidinduced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer. International journal of cancer Journal international du cancer. 2011; 128:332-342.
21. Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C and Wang Y. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2015; 21:2941-2951.
22. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN and Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer cell. 2004; 5:329-339.
23. Tumbarello DA, Temple J and Brenton JD. ss3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Molecular cancer. 2012; 11:36.
24. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer research. 2003; 63:7081-7088.
25. Sasaki H, Sheng Y, Kotsuji F and Tsang BK. Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer research. 2000; 60:5659-5666.
26. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK and Cheng JQ. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). The Journal of biological chemistry. 2004; 279:5405-5412.
27. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 2008; 14:7430-7437.
28. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A and Kristiansen G. Periostin is up-regulated in high grade and high stage prostate cancer. BMC cancer. 2010; 10:273.
29. Contie S, Voorzanger-Rousselot N, Litvin J, Clezardin P and Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. International journal of cancer Journal international du cancer. 2011; 128:352-360.
30. Sung PL, Chang YH, Chao KC, Chuang CM, Task Force on Systematic R and Meta-analysis of Ovarian C. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecologic oncology. 2014; 133:147-154.
31. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012; 481:85-89.
32. Chien J, Kuang R, Landen C and Shridhar V. Platinumsensitive recurrence in ovarian cancer: the role of tumor microenvironment. Frontiers in oncology. 2013; 3:251.
33. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E and Testa JR. Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res. 1997; 57:2116-2120.
34. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular cancer therapeutics. 2010; 9:1956-1967.
35. Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL and Hsu LC. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn-Schmiedeberg's archives of pharmacology. 2015; 388:19-31.
36. Zhang W, Ota T, Shridhar V, Chien J, Wu B and Kuang R. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. PLoS computational biology. 2013; 9:e1002975.
37. Petru E, Luck HJ, Stuart G, Gaffney D, Millan D, Vergote I and Gynecologic Cancer I. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. European journal of obstetrics, gynecology, and reproductive biology. 2009; 143:69-74.
38. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D and Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC cancer. 2006; 6:228.
39. Bookman MA, Greer BE and Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2003; 13:735-740.
40. Tsai HY, Yang YF, Wu AT, Yang CJ, Liu YP, Jan YH, Lee CH, Hsiao YW, Yeh CT, Shen CN, Lu PJ, Huang MS and Hsiao M. Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78. Oncogene. 2013; 32:4921-4931.
41. Vichai V and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature protocols. 2006; 1:1112-1116.
42. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews. 2006; 58:621-681.